Stopping the spread of Ebola will require close collaboration and engagement from stakeholders across the health care system, and the biopharmaceutical industry stands ready to do its part to assist patients and their families affected by this terrible virus. Over the past several years, biopharmaceutical researchers have been working to develop vaccines and treatments to prevent infection and fight its effects, and there are at least two Ebola vaccines currently in the pipeline.

PhRMA members are also helping to expand capacity on the ground in West Africa to take care of affected patients, including making product donations, providing funding to relief organizations for infrastructure improvements, medical products and protective equipment for health care workers, and donating funds for disease education and prevention efforts within the region.